369 related articles for article (PubMed ID: 28215935)
21. SVILE regimen, a combination of dexamethasone, vindesine, ifosfamide, pegaspargase, and etoposide, for treating relapsed/refractory extranodal natural killer/T-cell lymphoma, nasal type.
Wei L; Wang L; Cong J; Yang L; Ye J; Li X; Yao N; Yang J; Wang J
Leuk Res; 2020 Sep; 96():106422. PubMed ID: 32721642
[TBL] [Abstract][Full Text] [Related]
22. First-line LVDP (L-asparaginase, etoposide, dexamethasone, and cisplatin) regimen combined with radiotherapy is effective for early-stage extranodal natural killer/T-cell lymphoma, nasal type.
Wu W; Chen X; Li N; Luo Q; Zou L
Ann Hematol; 2022 Jul; 101(7):1557-1565. PubMed ID: 35585247
[TBL] [Abstract][Full Text] [Related]
23. Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study.
Yamaguchi M; Kwong YL; Kim WS; Maeda Y; Hashimoto C; Suh C; Izutsu K; Ishida F; Isobe Y; Sueoka E; Suzumiya J; Kodama T; Kimura H; Hyo R; Nakamura S; Oshimi K; Suzuki R
J Clin Oncol; 2011 Nov; 29(33):4410-6. PubMed ID: 21990393
[TBL] [Abstract][Full Text] [Related]
24. Phase II trial of concurrent chemoradiotherapy with L-asparaginase and MIDLE chemotherapy for newly diagnosed stage I/II extranodal NK/T-cell lymphoma, nasal type (CISL-1008).
Yoon DH; Kim SJ; Jeong SH; Shin DY; Bae SH; Hong J; Park SK; Yhim HY; Yang DH; Lee H; Kang HJ; Lee MH; Eom HS; Kwak JY; Lee JH; Suh C; Kim WS
Oncotarget; 2016 Dec; 7(51):85584-85591. PubMed ID: 27542213
[TBL] [Abstract][Full Text] [Related]
25. Concurrent Chemoradiation Therapy Followed by Consolidation Chemotherapy for Localized Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type.
Oh D; Ahn YC; Kim SJ; Kim WS; Ko YH
Int J Radiat Oncol Biol Phys; 2015 Nov; 93(3):677-83. PubMed ID: 26461010
[TBL] [Abstract][Full Text] [Related]
26. Primary radiotherapy showed favorable outcome in treating extranodal nasal-type NK/T-cell lymphoma in children and adolescents.
Wang ZY; Li YX; Wang WH; Jin J; Wang H; Song YW; Liu QF; Wang SL; Liu YP; Qi SN; Fang H; Liu XF; Yu ZH
Blood; 2009 Nov; 114(23):4771-6. PubMed ID: 19812381
[TBL] [Abstract][Full Text] [Related]
27. NF-kappaB activation through the alternative pathway correlates with chemoresistance and poor survival in extranodal NK/T-cell lymphoma, nasal type.
Liu X; Wang B; Ma X; Guo Y
Jpn J Clin Oncol; 2009 Jul; 39(7):418-24. PubMed ID: 19395464
[TBL] [Abstract][Full Text] [Related]
28. Combined chemotherapy and external beam radiation for stage IE and IIE natural killer T-cell lymphoma of nasal cavity.
Wang B; Lu JJ; Ma X; Guo Y; Lu H; Hong X; Li J
Leuk Lymphoma; 2007 Feb; 48(2):396-402. PubMed ID: 17325902
[TBL] [Abstract][Full Text] [Related]
29. Sustained remission of multi-line relapsed extranodal NK/T-cell lymphoma, nasal type, following sintilimab and chidamide: A case report.
Xu J; Xu X; Chen J; Wang J; Jiang C; Lv C; Chen B
Medicine (Baltimore); 2021 Mar; 100(10):e24824. PubMed ID: 33725836
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and Safety of a Pegasparaginase-Based Chemotherapy Regimen vs an L-asparaginase-Based Chemotherapy Regimen for Newly Diagnosed Advanced Extranodal Natural Killer/T-Cell Lymphoma: A Randomized Clinical Trial.
Wang X; Zhang L; Liu X; Li X; Li L; Fu X; Sun Z; Wu J; Zhang X; Yan J; Chang Y; Nan F; Zhou Z; Wu X; Tian L; Ma M; Li Z; Yu H; Zhu L; Wang Y; Shi C; Feng X; Li J; Ding M; Zhang J; Dong M; Xue H; Wang J; Zou L; Su L; Wu J; Liu L; Bao H; Zhang L; Guo Y; Guo S; Lu Y; Young KH; Li W; Zhang M
JAMA Oncol; 2022 Jul; 8(7):1035-1041. PubMed ID: 35708709
[TBL] [Abstract][Full Text] [Related]
31. L-asparaginase-based regimen in the treatment of refractory midline nasal/nasal-type T/NK-cell lymphoma.
Yong W; Zheng W; Zhang Y; Zhu J; Wei Y; Zhu D; Li J
Int J Hematol; 2003 Aug; 78(2):163-7. PubMed ID: 12953813
[TBL] [Abstract][Full Text] [Related]
32. [Analysis of prognostic factors of extranodal NK/T-cell lymphoma treated with pegaspargase/L-asparaginase: a multicenter retrospective study].
Shen ZY; Chen XC; Shan HR; Jia T; Gu WY; Wang F; Teng QL; Wang L; Wang CL; Shi YY; Zhang H; Miao YQ; Zhu TG; Ji CY; Ye JJ; Zhang MZ; Zhang XD; Wang L; Xu KL; Sang W
Zhonghua Xue Ye Xue Za Zhi; 2023 Aug; 44(8):642-648. PubMed ID: 37803837
[No Abstract] [Full Text] [Related]
33. Ki-67 Can Predict the Response to the Gemcitabine, Oxaliplatin And L-asparaginase Regimen (GELOX) and Prognosis in Patients with Nasal Natural Killer/T-cell Lymphoma.
Zhang J; Jiang W; Wang WD; Liu CC; Hu YP; Xia ZJ
Asian Pac J Cancer Prev; 2015; 16(11):4515-20. PubMed ID: 26107196
[TBL] [Abstract][Full Text] [Related]
34. Phase I/II study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: Japan Clinical Oncology Group Study JCOG0211.
Yamaguchi M; Tobinai K; Oguchi M; Ishizuka N; Kobayashi Y; Isobe Y; Ishizawa K; Maseki N; Itoh K; Usui N; Wasada I; Kinoshita T; Ohshima K; Matsuno Y; Terauchi T; Nawano S; Ishikura S; Kagami Y; Hotta T; Oshimi K
J Clin Oncol; 2009 Nov; 27(33):5594-600. PubMed ID: 19805668
[TBL] [Abstract][Full Text] [Related]
35. [Retrospective analyses of CHOPE plus L-asparaginase regimen in treatment of T-cell lymphoma].
Wan WL; Wang J; Zhu MX; Zhang W; Ke XY
Beijing Da Xue Xue Bao Yi Xue Ban; 2016 Oct; 48(5):841-845. PubMed ID: 27752167
[TBL] [Abstract][Full Text] [Related]
36. Outcomes of patients treated with SVILE
Wei L; Yang L; Ye J; Cong J; Li X; Yao N; Yang J; Cui X; Ding J; Wu Y; Wang J
Cancer Biol Med; 2020 Aug; 17(3):795-804. PubMed ID: 32944407
[No Abstract] [Full Text] [Related]
37. First-line combination of gemcitabine, oxaliplatin, and L-asparaginase (GELOX) followed by involved-field radiation therapy for patients with stage IE/IIE extranodal natural killer/T-cell lymphoma.
Wang L; Wang ZH; Chen XQ; Li YJ; Wang KF; Xia YF; Xia ZJ
Cancer; 2013 Jan; 119(2):348-55. PubMed ID: 22811078
[TBL] [Abstract][Full Text] [Related]
38. Phase I study of dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma and leukemia.
Yamaguchi M; Suzuki R; Kwong YL; Kim WS; Hasegawa Y; Izutsu K; Suzumiya J; Okamura T; Nakamura S; Kawa K; Oshimi K
Cancer Sci; 2008 May; 99(5):1016-20. PubMed ID: 18294294
[TBL] [Abstract][Full Text] [Related]
39. Comparison of the clinical efficacies of two L-asparaginase-based chemotherapy regimens for newly diagnosed nasal-type extranodal NK/T-cell lymphoma.
Wu W; Ren K; Chen X; Li N; Luo Q; Hai T; Zhou H; Zou L
Cancer Med; 2023 Apr; 12(8):9458-9470. PubMed ID: 37000008
[TBL] [Abstract][Full Text] [Related]
40. "Sandwich" protocol based on modified SMILE regimen for children with newly extranodal NK/T cell lymphoma, nasal type: a single-arm, single-center clinical study.
Shen CQ; He GQ; Wan Z; Lin C; Yang X; Lu XX; Zhu YP; Gao J; Guo X
Ann Hematol; 2023 Nov; 102(11):3143-3152. PubMed ID: 37486391
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
